Forte Biosciences Inc (FBRX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Forte Biosciences Inc (FBRX) has a cash flow conversion efficiency ratio of -0.166x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-14.00 Million) by net assets ($84.10 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See FBRX net asset quality score to measure how much of total assets are equity-financed.
Forte Biosciences Inc - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Forte Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore Forte Biosciences Inc (FBRX) cash flow to debt to assess how comfortably operating cash covers total debt obligations.
Forte Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Forte Biosciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Cartesian Therapeutics Inc.
NASDAQ:RNAC
|
0.149x |
|
RADCOM Ltd
F:RAM
|
N/A |
|
New World Resources Ltd
AU:NWC
|
-0.015x |
|
Value Added Technology Co. Ltd
KQ:043150
|
0.022x |
|
Terra Santa Propriedades Agrícolas S.A.
SA:LAND3
|
0.070x |
|
Sriracha Construction Public Company Limited
BK:SRICHA
|
0.699x |
|
Galectin Therapeutics Inc
NASDAQ:GALT
|
0.030x |
|
Jean Co Ltd
TW:2442
|
0.583x |
Annual Cash Flow Conversion Efficiency for Forte Biosciences Inc (2015–2024)
The table below shows the annual cash flow conversion efficiency of Forte Biosciences Inc from 2015 to 2024. For the full company profile with market capitalisation and key ratios, see Forte Biosciences Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $52.48 Million | $-30.75 Million | -0.586x | +27.93% |
| 2023-12-31 | $35.31 Million | $-28.71 Million | -0.813x | -285.51% |
| 2022-12-31 | $38.82 Million | $-8.19 Million | -0.211x | +47.47% |
| 2021-12-31 | $41.55 Million | $-16.68 Million | -0.401x | -28.50% |
| 2020-12-31 | $58.98 Million | $-18.42 Million | -0.312x | +35.23% |
| 2019-12-31 | $5.75 Million | $-2.77 Million | -0.482x | +18.65% |
| 2018-12-31 | $58.15 Million | $-34.47 Million | -0.593x | -35.35% |
| 2017-12-31 | $71.08 Million | $-31.13 Million | -0.438x | +89.63% |
| 2016-12-31 | $7.00 Million | $-29.54 Million | -4.222x | -684.24% |
| 2015-12-31 | $39.08 Million | $-21.04 Million | -0.538x | -- |
About Forte Biosciences Inc
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as graft-vs-host disease, vitiligo, and alopecia areata, as well as for celiac disease and non-segmental vitiligo. … Read more